Phase I study of docetaxel with concomitant thoracic radiation therapy.

  title={Phase I study of docetaxel with concomitant thoracic radiation therapy.},
  author={Ann M. Mauer and Gregory A. Masters and Daniel J. Haraf and Philip C. Hoffman and Scott M. Watson and Harvey M. Golomb and Everett E. Vokes},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={16 1},
PURPOSE The taxanes have demonstrated activity as radiation sensitizers in preclinical studies. This study was designed to determine the maximum-tolerated dose (MTD), optimal schedule, and toxicities of docetaxel in combination with concomitant standard chest radiotherapy. PATIENTS AND METHODS Twenty-nine patients with advanced non-small-cell lung or esophageal cancer enrolled in this phase I study to evaluate escalating docetaxel doses at three schedules. Docetaxel was administered as two 21… CONTINUE READING